DermTech Inc
DMTK
$0.61
Closing
▼-0.32%
1D
▼-64.91%
YTD
Market cap
$
52 week high
$3.93
52 week low
$0.58
Volume
4,564
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$
Analysts' Rating
BUY
Price Target (Mean)
3.6
Total Analysts
6
P/E
Operating Margin
-506.00%
Beta
2.54
Revenue Growth (Annual)
22.64%
52 week high
$3.93
52 week low
$0.58
Div. Yield
%
EPS Annual Growth
-42.42
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
DermTech, Inc. is a molecular diagnostics company. The Company is focused on developing and marketing non-invasive genomics tests to aid in the diagnosis and management of skin cancer, inflammatory skin diseases, and aging-related skin conditions. Its technology enhances early melanoma detection by non-invasively detecting genomic markers associated with melanoma to identify higher risk lesions at their earliest stages to rule out melanoma. It provides genomic analysis of skin samples collected non-invasively using its Smart Stickers. Its DermTech Melanoma Test (the DMT) facilitates the clinical assessment of pigmented skin lesions that raise the concern for melanoma. Its commercial test addresses unmet needs in the diagnostic pathway of pigmented skin lesions, dark-colored patches of skin often referred to as moles. It markets the DMT under the name Pigmented Lesion Assay (PLA). It is also focuses on products to assess precancerous genomic changes associated with UV sun exposure.
